The clinical trial for Nitroketazine, sponsored by Peking University Third Hospital, aims to evaluate the efficacy and safety of this treatment in ALS patients. With an estimated enrollment of 150 patients, the study is currently recruiting and is designed as a multicenter, randomized, double-blind, placebo-controlled trial. The ALS market is characterized by a high unmet need, with limited treatment options currently available. Successful outcomes could position Nitroketazine as a significant player in the ALS treatment landscape, potentially leading to market exclusivity if patent protections are secured. The competitive landscape includes existing therapies such as Riluzole and Edaravone, which may face challenges if Nitroketazine demonstrates superior efficacy or safety profiles.